vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and MONRO, INC. (MNRO). Click either name above to swap in a different company.
MONRO, INC. is the larger business by last-quarter revenue ($293.4M vs $281.3M, roughly 1.0× Guardant Health, Inc.). MONRO, INC. runs the higher net margin — 3.8% vs -45.7%, a 49.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -4.0%). MONRO, INC. produced more free cash flow last quarter ($9.1M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -2.7%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Monro, Inc. is an automotive services company founded and headquartered in Rochester, New York, U.S. As of 2025, Monro has 1,260 locations making them the second-largest automotive services company in North America after Driven Brands by number of locations and by revenue.
GH vs MNRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $293.4M |
| Net Profit | $-128.5M | $11.1M |
| Gross Margin | 64.6% | 34.9% |
| Operating Margin | -43.0% | 6.3% |
| Net Margin | -45.7% | 3.8% |
| Revenue YoY | 39.4% | -4.0% |
| Net Profit YoY | -15.8% | 143.1% |
| EPS (diluted) | $-1.01 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $293.4M | ||
| Q3 25 | $265.2M | $288.9M | ||
| Q2 25 | $232.1M | $301.0M | ||
| Q1 25 | $203.5M | $295.0M | ||
| Q4 24 | $201.8M | $305.8M | ||
| Q3 24 | $191.5M | $301.4M | ||
| Q2 24 | $177.2M | $293.2M | ||
| Q1 24 | $168.5M | $310.1M |
| Q4 25 | $-128.5M | $11.1M | ||
| Q3 25 | $-92.7M | $5.7M | ||
| Q2 25 | $-99.9M | $-8.1M | ||
| Q1 25 | $-95.2M | $-21.3M | ||
| Q4 24 | $-111.0M | $4.6M | ||
| Q3 24 | $-107.8M | $5.6M | ||
| Q2 24 | $-102.6M | $5.9M | ||
| Q1 24 | $-115.0M | $3.7M |
| Q4 25 | 64.6% | 34.9% | ||
| Q3 25 | 64.7% | 35.7% | ||
| Q2 25 | 65.0% | 35.5% | ||
| Q1 25 | 63.3% | 33.0% | ||
| Q4 24 | 61.6% | 34.3% | ||
| Q3 24 | 61.1% | 35.3% | ||
| Q2 24 | 59.1% | 37.2% | ||
| Q1 24 | 61.2% | 35.5% |
| Q4 25 | -43.0% | 6.3% | ||
| Q3 25 | -37.3% | 4.4% | ||
| Q2 25 | -45.9% | -2.0% | ||
| Q1 25 | -54.6% | -8.1% | ||
| Q4 24 | -62.4% | 3.3% | ||
| Q3 24 | -61.3% | 4.4% | ||
| Q2 24 | -56.8% | 4.5% | ||
| Q1 24 | -59.2% | 3.3% |
| Q4 25 | -45.7% | 3.8% | ||
| Q3 25 | -35.0% | 2.0% | ||
| Q2 25 | -43.0% | -2.7% | ||
| Q1 25 | -46.8% | -7.2% | ||
| Q4 24 | -55.0% | 1.5% | ||
| Q3 24 | -56.3% | 1.9% | ||
| Q2 24 | -57.9% | 2.0% | ||
| Q1 24 | -68.2% | 1.2% |
| Q4 25 | $-1.01 | $0.35 | ||
| Q3 25 | $-0.74 | $0.18 | ||
| Q2 25 | $-0.80 | $-0.28 | ||
| Q1 25 | $-0.77 | $-0.74 | ||
| Q4 24 | $-0.90 | $0.15 | ||
| Q3 24 | $-0.88 | $0.18 | ||
| Q2 24 | $-0.84 | $0.19 | ||
| Q1 24 | $-0.94 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $4.9M |
| Total DebtLower is stronger | $1.5B | $45.0M |
| Stockholders' EquityBook value | $-99.3M | $604.9M |
| Total Assets | $2.0B | $1.6B |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $4.9M | ||
| Q3 25 | $580.0M | $10.5M | ||
| Q2 25 | $629.1M | $7.8M | ||
| Q1 25 | $698.6M | $20.8M | ||
| Q4 24 | $525.5M | $10.2M | ||
| Q3 24 | $585.0M | $20.9M | ||
| Q2 24 | $933.7M | $18.7M | ||
| Q1 24 | $1.0B | $6.6M |
| Q4 25 | $1.5B | $45.0M | ||
| Q3 25 | $1.1B | $60.0M | ||
| Q2 25 | $1.1B | $71.5M | ||
| Q1 25 | $1.1B | $61.3M | ||
| Q4 24 | $1.1B | $59.3M | ||
| Q3 24 | — | $62.0M | ||
| Q2 24 | — | $112.0M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $-99.3M | $604.9M | ||
| Q3 25 | $-354.5M | $601.7M | ||
| Q2 25 | $-305.5M | $604.9M | ||
| Q1 25 | $-250.8M | $620.8M | ||
| Q4 24 | $-139.6M | $648.9M | ||
| Q3 24 | $-60.1M | $651.9M | ||
| Q2 24 | $-1.6M | $654.4M | ||
| Q1 24 | $68.3M | $656.8M |
| Q4 25 | $2.0B | $1.6B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.5B | $1.7B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.6B | $1.7B | ||
| Q1 24 | $1.7B | $1.7B |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.10× | ||
| Q4 24 | — | 0.09× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.17× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $17.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $9.1M |
| FCF MarginFCF / Revenue | -19.3% | 3.1% |
| Capex IntensityCapex / Revenue | 9.9% | 3.0% |
| Cash ConversionOCF / Net Profit | — | 1.60× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $49.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $17.8M | ||
| Q3 25 | $-35.4M | $32.3M | ||
| Q2 25 | $-60.3M | $-1.9M | ||
| Q1 25 | $-62.7M | $28.9M | ||
| Q4 24 | $-64.5M | $14.8M | ||
| Q3 24 | $-51.1M | $62.6M | ||
| Q2 24 | $-94.0M | $25.6M | ||
| Q1 24 | $-30.3M | $-5.3M |
| Q4 25 | $-54.2M | $9.1M | ||
| Q3 25 | $-45.8M | $26.6M | ||
| Q2 25 | $-65.9M | $-9.3M | ||
| Q1 25 | $-67.1M | $23.2M | ||
| Q4 24 | $-83.4M | $7.9M | ||
| Q3 24 | $-55.3M | $57.6M | ||
| Q2 24 | $-99.1M | $16.8M | ||
| Q1 24 | $-37.2M | $-11.9M |
| Q4 25 | -19.3% | 3.1% | ||
| Q3 25 | -17.3% | 9.2% | ||
| Q2 25 | -28.4% | -3.1% | ||
| Q1 25 | -33.0% | 7.9% | ||
| Q4 24 | -41.3% | 2.6% | ||
| Q3 24 | -28.9% | 19.1% | ||
| Q2 24 | -55.9% | 5.7% | ||
| Q1 24 | -22.1% | -3.8% |
| Q4 25 | 9.9% | 3.0% | ||
| Q3 25 | 3.9% | 2.0% | ||
| Q2 25 | 2.4% | 2.5% | ||
| Q1 25 | 2.2% | 1.9% | ||
| Q4 24 | 9.4% | 2.2% | ||
| Q3 24 | 2.2% | 1.6% | ||
| Q2 24 | 2.9% | 3.0% | ||
| Q1 24 | 4.1% | 2.1% |
| Q4 25 | — | 1.60× | ||
| Q3 25 | — | 5.71× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.23× | ||
| Q3 24 | — | 11.08× | ||
| Q2 24 | — | 4.37× | ||
| Q1 24 | — | -1.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
MNRO
| Tires | $150.2M | 51% |
| Maintenance | $73.5M | 25% |
| Brakes | $35.1M | 12% |
| Steering | $24.9M | 8% |
| Batteries | $6.2M | 2% |
| Exhaust | $3.2M | 1% |
